1. Estimating the Force of Infection for Dengue Virus Using Repeated Serosurveys, Ouagadougou, Burkina Faso
- Author
-
Kang Sung Lee, Ahmed Barro, Emmanuel Bonnet, Suk Namkung, Thérèse Kagoné, Losseni Kaba, Paul-André Somé, Tansy Edwards, Jacqueline Kyungah Lim, Mabel Carabali, Jae Seung Yang, In-Kyu Yoon, Jung-Seok Lee, Mee Young Shin, Teguewende Nikiema, Valéry Ridde, Yaro Seydou, Neal Alexander, Désiré Lucien Dahourou, International Vaccine Institute (IVI), London School of Hygiene and Tropical Medicine (LSHTM), McGill University = Université McGill [Montréal, Canada], Centre Muraz [Bobo-Dioulasso, Burkina Faso], Institut de Recherche en Sciences de la Santé Bobo Dioulasso (INSSA), Université Polytechnique Nazi Boni Bobo-Dioulasso (UNB), Risques, Ecosystèmes, Vulnérabilité, Environnement, Résilience (RECOVER), Aix Marseille Université (AMU)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre National de Transfusion Sanguine, Ouagadougou, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPCité), Coalition for Epidemic Preparedness Innovations [Washington, DC, États-Unis] (CEPI), he Bill and Melinda Gates Foundation (grant no. OPP 1053432), as well as funding from the governments of Sweden, India,and South Korea. This research project was part of the 'Community Research Studies and Interventions forHealth Equity in Burkina Faso' program, funded by the Canadian Institutes of Health Research (ROH-115213).award MR/R010161/1,which is jointly funded by the UK Medical Research Council (MRC) and the UK Department for InternationalDevelopment (DFID) under the MRC/DFID Concordat agreement and is also part of the European and Developing Countries Clinical Trials Partnership (EDCTP) -2 program, supported by the European Union., Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Pôle de recherche pour l'organisation et la diffusion de l'information géographique (PRODIG (UMR_8586 / UMR_D_215 / UM_115)), and Université Paris 1 Panthéon-Sorbonne (UP1)-Institut de Recherche pour le Développement (IRD)-AgroParisTech-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
- Subjects
Epidemiology ,Binomial regression ,lcsh:Medicine ,Force of infection ,CHILDREN ,Dengue virus ,medicine.disease_cause ,Disease Outbreaks ,Dengue fever ,Serology ,Estimating the Force of Infection for Dengue Virus Using Repeated Serosurveys, Ouagadougou, Burkina Faso ,0302 clinical medicine ,030212 general & internal medicine ,BURKINA FASO ,Constant force ,Aedes mosquitoes ,ComputingMilieux_MISCELLANEOUS ,SEROPREVALENCE ,3. Good health ,PREVALENCE ,Infectious Diseases ,EPIDEMIC FEVER ,cross reactivity ,outbreaks ,Child, Preschool ,ZABR ,force of infection ,Microbiology (medical) ,IgG ,TRANSMISSION ,030231 tropical medicine ,regression models ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,medicine ,Humans ,lcsh:RC109-216 ,viruses ,population seroprevalence ,Seroconversion ,seroconversion ,LINKED-IMMUNOSORBENT-ASSAY ,business.industry ,Research ,lcsh:R ,Infant ,Outbreak ,Dengue Virus ,medicine.disease ,dengue ,HEMAGGLUTINATION INHIBITION ,OUAGADOUGOU ,Africa ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,flaviviruses ,Demography - Abstract
Because of limited data on dengue virus in Burkina Faso, we conducted 4 consecutive age-stratified longitudinal serologic surveys, ≈6 months apart, among persons 1-55 years of age, during June 2015-March 2017, which included a 2016 outbreak. The seroconversion rate before the serosurvey enrollment was estimated by binomial regression, taking age as the duration of exposure, and assuming constant force of infection (FOI) over age and calendar time. We calculated FOI between consecutive surveys and rate ratios for potentially associated characteristics based on seroconversion using the duration of intervals. Among 2,897 persons at enrollment, 66.3% were IgG-positive, and estimated annual FOI was 5.95%. Of 1,269 enrollees participating in all 4 serosurveys, 438 were IgG-negative at enrollment. The annualized FOI ranged from 10% to 20% (during the 2016 outbreak). Overall, we observed high FOI for dengue. These results could support decision-making about control and preventive measures for dengue
- Published
- 2021
- Full Text
- View/download PDF